Bicara enables access to the thriving innovation ecosystem which accelerates our development of therapies for cancer. Synergies between the Bicara teams in Boston and Bengaluru will pioneer breakthrough innovation.
Total raised: $635M
Investors 8
| Date | Name | Website |
| 24.02.2024 | Aisling Ca... | aislingcap... |
| 13.07.2025 | Foresite C... | foresiteca... |
| 04.04.2023 | Omega Fund... | omegafunds... |
| 06.03.2023 | F-Prime Ca... | fprimecapi... |
| 05.04.2022 | Cavendish ... | cavendishf... |
| 03.11.2022 | Red Tree V... | redtreevc.... |
| - | Bioqube Ve... | bioqubeven... |
| 13.11.2023 | Eight Road... | eightroads... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 21.09.2024 | IPO | $362M | - |
| 10.01.2024 | Series C | $165M | - |
| 24.03.2023 | Series B | $108M | Janus Hend... |
Mentions in press and media 21
| Date | Title | Description |
| 21.09.2024 | Bicara Therapeutics Soars with $362 Million IPO: A New Dawn for Cancer Treatment | Bicara Therapeutics Inc. has made a significant splash in the biopharmaceutical pool. The company recently closed its initial public offering (IPO), raising a staggering $362 million. This move marks a pivotal moment for a firm dedicated to... |
| 21.09.2024 | Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares | BOSTON, Sept. 16, 2024 (GLOBE NEWSWIRE) — Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for patients with solid tumors, today announced the cl... |
| 16.09.2024 | Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares | BOSTON, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for patients with solid tumors, today announced the c... |
| 07.09.2024 | Bicara Therapeutics Expands Clinical Team with Appointments of Jeltje Schulten, M.D., MBA, as SVP of Clinical and Medical Affairs and Rita Dalal, MBBS, MPH, as VP of Clinical Development | BOSTON, Mass., March 26, 2024 – Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today announced the appointments of Jeltje Schulten, M.D., MBA, as ... |
| 07.09.2024 | Bicara Therapeutics Reports Updated Interim Phase 1/1b Data of Ficerafusp Alfa (BCA101) in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) | First-in-class bifunctional EGFR/TGF-β inhibitor, ficerafusp alfa, in combination with pembrolizumab has demonstrated clinically meaningful anti-tumor activity and significant improvement over standard of care in HNSCC with at least 12 mont... |
| 07.09.2024 | Bicara Therapeutics Expands Board of Directors with Appointments of Mike Powell, Ph.D., and Christopher Bowden, M.D. | BOSTON, Mass., August 15, 2024 – Bicara Therapeutics, a clinical-stage biotechnology company developing transformative bifunctional therapies for patients with solid tumors, today announced the appointments of Mike Powell, Ph.D., and Christ... |
| 10.01.2024 | Bicara Therapeutics Announces Oversubscribed $165 Million Series C Financing | Proceeds to accelerate clinical development of first-in-class bifunctional EGFR/TGF-β inhibitor, BCA101, for multiple cancer types, including 1L HPV-negative recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) |
| 20.12.2023 | Bicara Therapeutics: Clinical-Stage Biotechnology Company Raises Oversubscribed $165 Million Funding Round | Bicara Therapeutics – a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response – recently announced the completion of an oversubscribed $165 million Series C financing. The fundi... |
| 13.12.2023 | Bicara Therapeutics Raises $165M in Series C Financing | Bicara Therapeutics, a Boston, MA-based clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, closed a $165m Series C financing. The round was co-led by Braidwell LP and TPG, w... |
| 12.12.2023 | Bicara Therapeutics Announces Oversubscribed $165 Million Series C Financing | - |
Show more